Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study

Table 4 Risk factors for tumor recurrence and death in the combined hepatocellular carcinoma and cholangiocarcinoma group

Tumor recurrence				Death
	OR	95%CI	P value		OR	95%CI	P value
Univariate				Univariate
Sex (male)	4.763	1.155-19.640	0.031	Sex (male)	6.464	0.883-47.317	0.066
Recipient age	0.999	0.958-1.041	0.957	Recipient age	1.005	0.957-1.057	0.833
Locoregional therapy before LT	1.724	0.907-3.274	0.096	Locoregional therapy before LT	1.924	0.891-4.153	0.096
TACE before LT	1.826	0.989-3.371	0.054	TACE before LT	2.188	1.039-4.609	0.039
Liver resection before LT	2.594	1.387-4.852	0.003	Liver resection before LT	0.941	0.365-2.428	0.9
RFA before LT	1.616	0.781-3.340	0.196	RFA before LT	2.284	1.025-5.090	0.043
Radiation therapy before LT	0.718	0.174-2.962	0.646	Radiation therapy before LT	0.654	0.089-4.813	0.677
Number of locoregional therapies before LT > 3	1.068	1.002-1.138	0.043	Number of locoregional therapies before LT > 3	1.733	0.865-3.473	0.121
MELD	0.993	0.950-1.038	0.742	MELD	1.012	0.965-1.063	0.617
Type of LT (DDLT)	0.934	0.397-2.198	0.875	Type of LT (DDLT)	1.518	0.626-3.680	0.365
ABO-incompatibility	1.563	0.618-3.952	0.345	ABO-incompatibility	0.79	0.189-3.297	0.746
Tumor size > 3cm	3.013	1.707-5.317	< 0.001	Tumor size > 3 cm	3.462	1.740-6.888	< 0.001
Tumor number > 3	1.35	0.723-2.520	0.346	Tumor number > 3	1.463	0.694-3.084	0.318
Milan criteria (beyond)	2.495	1.403-4.436	0.002	Milan criteria (beyond)	2.813	1.395-5.670	0.004
Tumor grade 3 or 4	1.465	0.809-2.651	0.208	Tumor grade 3 or 4	1.229	0.586-2.580	0.585
Microvascular invasion	2.417	1.360-4.297	0.003	Microvascular invasion	2.28	1.153-4.507	0.018
PVTT	1.416	0.661-3.032	0.37	PVTT	1.302	0.502-3.376	0.587
BDTT	0.047	0.000-36.844	0.368	BDTT	0.048	0.000-333.805	0.5
Intrahepatic metastasis	1.357	0.676-2.722	0.39	Intrahepatic metastasis	1.182	0.515-2.716	0.693
Multicentric occurrence	1.148	0.607-2.170	0.671	Multicentric occurrence	1.125	0.526-2.403	0.762
Encapsulation	1.269	0.582-2.766	0.549	Encapsulation	0.952	0.367-2.471	0.92
Tumor necrosis	2.361	1.302-4.281	0.005	Tumor necrosis	3.22	1.531-6.773	0.002
Dominant type (CC)	0.995	0.495-2.003	0.989	Dominant type (CC)	0.823	0.375-1.805	0.627
Lymph node metastasis	13.954	3.065-63.526	0.001	Lymph node metastasis	24.719	4.683-130.472	< 0.001
AFP > 20 ng/mL	1.563	0.880-2.777	0.128	AFP > 20 ng/mL	1.527	0.769-3.033	0.226
PIVKA-II > 40 mAU/mL	1.067	0.576-1.975	0.837	PIVKA-II > 40 mAU/mL	1.762	0.865-3.589	0.118
Multivariate				Multivariate
Number of locoregional therapies before LT > 3	1.813	1.012-3.248	0.046	Tumor size > 3 cm	4.591	1.851-11.390	0.001
Tumor size > 3 cm	2.378	1.321-4.280	0.004
Lymph node metastasis	8.585	1.822-40.453	0.007

OR: Odds ratio; CI: Confidence interval; LT: Liver transplantation; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; MELD: Model for end-stage liver disease; DDLT: Deceased donor liver transplantation; PVTT: Portal vein tumor thrombosis; BDTT: Bile duct tumor thrombosis; CC: Cholangiocarcinoma; AFP: Alpha-fetoprotein; PIVKA-II: Prothrombin-induced by vitamin K absence-II.